Melanoma Clinical Trials

Showing 281-300 of 705 trials

CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors

NCT03511391

This randomized controlled phase II trial will investigate whether the addition of stereotactic body radiotherapy to checkpoint inhibitor treatment in patients with non-small-cell lung carcinoma, urothelial carcinoma, renal cell carcinoma, melanoma or head-and-neck carcinoma can improve progression-free survival as compared to checkpoint inhibitor monotherapy. The primary outcome is progression-free survival; secondary outcomes include overall survival, response according to iRecist and Recist v1.1 and toxicity.

Urothelial CarcinomaMelanomaRenal Cell Carcinoma+2 more

University Hospital, Ghent99 participantsStarted Mar 2018

Ghent, Oost-Vlaanderen, Belgium • Bruges, West-Vlaanderen, Belgium • Antwerp, Belgium +2 more locations

COMPLETEDPHASE2

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00866840

RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This phase II trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.

Melanoma (Skin)

Rutgers, The State University of New Jersey13 participantsStarted Apr 2009

New Brunswick, New Jersey, United States

COMPLETED

A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

NCT05432622

The purpose of this study is to examine real-world data among participants with stage IIIa melanoma initiating nivolumab as adjuvant treatment in the community practice setting by utilizing patient data from the United States Oncology Network (USON) iKnowMed (iKM) electronic health records (EHR) database.

Melanoma

Bristol-Myers Squibb95 participantsStarted Dec 2019

The Woodlands, Texas, United States

CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

Related Searches

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma

Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Long-Term Follow-Up Study of Patients Receiving ATL001

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Assessing Gene-Environment Interactions in Clinical Presentation of Nevi and Melanoma

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"